

WED, OCT 11, 11:30 AM – 12:30 PM CT • REGENCY A (BALLROOM LEVEL, WEST TOWER)

# SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

## SWOG CTP Update Forum *Behind the Scenes and on Stage*

### ATTEND TO LEARN ABOUT ...

- The CTP process: from a joint SWOG Committee/Industry Partner “idea” to protocol activation
- Several SWOG CTP projects, fully industry funded, now nearing final stages of contracting and development

#### 21CTP.GU01

Phase II study in first-line muscle-invasive bladder cancer with multiple arms of neoadjuvant therapy defined by molecular subtype

#### 21CTP.HN01

Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies

#### 21CTP.LEUK01

Phase II trial for patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia

- Other projects SWOG CTP has in development
- What SWOG sites can expect for SWOG CTP trials
  - Study feasibility and site selection process
  - Site funding and contracts
  - CTP systems – EDC, eISF, IRB

**All are invited!**

### SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH

For more information, visit

[swogctp.org](http://swogctp.org)

Email us at [CTP@swog.org](mailto:CTP@swog.org)

### TROPION-Breast03

In another model, SWOG CTP provides scientific leadership and is lead academic group for this global AstraZeneca-sponsored registration trial. Over 40 SWOG sites selected and in process of activation or are enrolling.